

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
 Organization
 International Bureau




(43) International Publication Date
 29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/034903 A1

- (51) International Patent Classification⁷: **A61B 5/0472**, G01N 33/68
 (21) International Application Number: PCT/GB2003/004541
 (22) International Filing Date: 21 October 2003 (21.10.2003)
 (25) Filing Language: English
 (26) Publication Language: English
 (30) Priority Data: 0224425.9 21 October 2002 (21.10.2002) GB
 (71) Applicant (for all designated States except US): **UNIVERSITY OF LEICESTER** [GB/GB]; Dept. of Medicine and Therapeutics, Clinical Sciences Building, Leicester LE2 7LX (GB).
 (72) Inventor; and
 (75) Inventor/Applicant (for US only): **NG, Leong, Loke** [CN/GB]; 35 Shirley Avenue, Leicester LE2 3NB (GB).
 (54) Title: **METHOD FOR PREDICTION OF CARDIAC DISEASE**
 (74) Agents: **ROBERTS, Gwilym, Vaughan et al.**; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).
 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
 (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
 Published: with international search report

[Continued on next page]



(57) Abstract: A method for screening patients for heart failure such as left ventricular systolic dysfunction (LVSD) comprises measuring a biomarker and taking an ECG measurement and combining both as factors to obtain a result indicative of the probability of the patient having heart failure. As a result the level of accuracy of the screening is significantly increased. Preferred biomarkers are natriuretic peptides (e.g. ANP, BNP).